Focused on the accuracy of PD-L1 IHC assays in order to identify patients with urothelial carcinomas to be treated with Pembrolizumab as immune therapy, PD-L1, Clone CAL10 (RBK063) – Assessment Results.
Focused on the accuracy of PD-L1 IHC assays in order to identify patients with non-small cell lung carcinoma (NSCLC) benefitting from immune therapy with Pembrolizumab, PD-L1, Clone CAL10 (RBK063) – Assessment Results.
In the difficult situation of the ongoing corona pandemic, we strive to keep both our deliveries and our service for you as usual.
Many of our employees are in the home office. Everyone can still be reached by email or phone. We ask for your understanding that all workshops and events planned in the near future have to be postponed until further notice upon the advice of the Federal Ministry of Health. We want to act responsibly to contribute at best to the fastest possible containment of the corona virus and the resulting COVID-19 disease.
Within the company, operations are currently largely unrestricted. We will get back to you as soon as a changed situation will prevent us from maintaining the same service as we usually do.
Your management of Zytomed Systems GmbH